Total Liabilities Summary of Exelixis, Inc.

Exelixis, Inc.'s latest annual total liabilities in 2023 was 678.44 Million USD , up 16.36% from previous year.
Exelixis, Inc.'s latest quarterly total liabilities in 2024 Q1 was 675.74 Million USD , down -0.4% from previous quarter.
Exelixis, Inc. reported annual total liabilities of 583.06 Million USD in 2022, up 43.74% from previous year.
Exelixis, Inc. reported annual total liabilities of 405.62 Million USD in 2021, up 57.08% from previous year.
Exelixis, Inc. reported quarterly total liabilities of 629.29 Million USD for 2023 Q3, up 2.4% from previous quarter.
Exelixis, Inc. reported quarterly total liabilities of 588.22 Million USD for 2023 Q1, up 0.89% from previous quarter.

Annual Total Liabilities Chart of Exelixis, Inc. (2023 - 1998)

Historical Annual Total Liabilities of Exelixis, Inc. (2023 - 1998)

Year	Total Liabilities	Total Liabilities Growth
2023	678.44 Million USD	16.36%
2022	583.06 Million USD	43.74%
2021	405.62 Million USD	57.08%
2020	258.22 Million USD	29.3%
2019	199.7 Million USD	48.11%
2018	134.83 Million USD	-63.59%
2017	370.33 Million USD	-27.13%
2016	508.22 Million USD	16.39%
2015	436.64 Million USD	-1.39%
2014	442.78 Million USD	1.31%
2013	437.04 Million USD	2.92%
2012	424.66 Million USD	40.32%
2011	302.63 Million USD	-48.63%
2010	589.11 Million USD	16.17%
2009	507.13 Million USD	10.76%
2008	457.88 Million USD	40.19%
2007	326.6 Million USD	7.15%
2006	304.8 Million USD	10.67%
2005	275.41 Million USD	14.44%
2004	240.66 Million USD	22.6%
2003	196.31 Million USD	20.29%
2002	163.19 Million USD	49.18%
2001	109.39 Million USD	165.93%
2000	41.13 Million USD	89.57%
1999	21.7 Million USD	-50.73%
1998	44.04 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	675.74 Million USD	-0.4%
2023 Q3	629.29 Million USD	2.4%
2023 Q1	588.22 Million USD	0.89%
2023 Q2	614.53 Million USD	4.47%
2023 Q4	678.44 Million USD	7.81%
2023 FY	678.44 Million USD	16.36%
2022 Q3	469.97 Million USD	-4.12%
2022 Q2	490.14 Million USD	36.05%
2022 Q1	360.26 Million USD	-11.18%
2022 Q4	583.06 Million USD	24.06%
2022 FY	583.06 Million USD	43.74%
2021 Q3	335.29 Million USD	3.42%
2021 Q4	405.62 Million USD	20.98%
2021 Q2	324.19 Million USD	16.05%
2021 FY	405.62 Million USD	57.08%
2021 Q1	279.35 Million USD	8.18%
2020 Q2	213.22 Million USD	2.54%
2020 Q1	207.95 Million USD	4.13%
2020 FY	258.22 Million USD	29.3%
2020 Q3	259.01 Million USD	21.47%
2020 Q4	258.22 Million USD	-0.31%
2019 Q1	156.77 Million USD	16.27%
2019 Q2	154.46 Million USD	-1.47%
2019 FY	199.7 Million USD	48.11%
2019 Q3	181.14 Million USD	17.27%
2019 Q4	199.7 Million USD	10.24%
2018 Q2	136.19 Million USD	29.52%
2018 FY	134.83 Million USD	-63.59%
2018 Q4	134.83 Million USD	24.38%
2018 Q3	108.4 Million USD	-20.41%
2018 Q1	105.14 Million USD	-71.61%
2017 Q2	368.02 Million USD	-21.23%
2017 FY	370.33 Million USD	-27.13%
2017 Q4	370.33 Million USD	-0.2%
2017 Q3	371.05 Million USD	0.82%
2017 Q1	467.23 Million USD	-8.07%
2016 Q3	516.46 Million USD	-22.13%
2016 Q4	508.22 Million USD	-1.6%
2016 Q1	648.48 Million USD	48.52%
2016 Q2	663.27 Million USD	2.28%
2016 FY	508.22 Million USD	16.39%
2015 Q2	436.96 Million USD	1.69%
2015 Q3	437.46 Million USD	0.12%
2015 Q4	436.64 Million USD	-0.19%
2015 Q1	429.69 Million USD	-2.96%
2015 FY	436.64 Million USD	-1.39%
2014 FY	442.78 Million USD	1.31%
2014 Q4	442.78 Million USD	0.14%
2014 Q1	426.08 Million USD	-2.51%
2014 Q3	442.16 Million USD	1.09%
2014 Q2	437.39 Million USD	2.65%
2013 Q1	404.67 Million USD	-4.71%
2013 FY	437.04 Million USD	2.92%
2013 Q4	437.04 Million USD	3.27%
2013 Q3	423.19 Million USD	1.79%
2013 Q2	415.75 Million USD	2.74%
2012 Q3	421.76 Million USD	53.13%
2012 FY	424.66 Million USD	40.32%
2012 Q4	424.66 Million USD	0.69%
2012 Q1	280.25 Million USD	-7.39%
2012 Q2	275.43 Million USD	-1.72%
2011 Q1	564.48 Million USD	-4.18%
2011 FY	302.63 Million USD	-48.63%
2011 Q4	302.63 Million USD	-25.93%
2011 Q3	408.58 Million USD	-23.77%
2011 Q2	535.99 Million USD	-5.05%
2010 Q2	634.41 Million USD	31.21%
2010 Q1	483.5 Million USD	-4.66%
2010 Q3	590.49 Million USD	-6.92%
2010 FY	589.11 Million USD	16.17%
2010 Q4	589.11 Million USD	-0.23%
2009 Q4	507.13 Million USD	-10.06%
2009 FY	507.13 Million USD	10.76%
2009 Q2	456.79 Million USD	2.87%
2009 Q1	444.05 Million USD	-3.02%
2009 Q3	563.87 Million USD	23.44%
2008 Q4	457.88 Million USD	64.58%
2008 FY	457.88 Million USD	40.19%
2008 Q2	304.56 Million USD	-5.17%
2008 Q3	278.21 Million USD	-8.65%
2008 Q1	321.17 Million USD	-1.66%
2007 FY	326.6 Million USD	7.15%
2007 Q4	326.6 Million USD	2.17%
2007 Q3	319.65 Million USD	-2.54%
2007 Q2	327.98 Million USD	-6.6%
2007 Q1	351.16 Million USD	15.21%
2006 Q2	255.01 Million USD	-15.85%
2006 Q1	303.06 Million USD	10.04%
2006 Q4	304.8 Million USD	24.25%
2006 FY	304.8 Million USD	10.67%
2006 Q3	245.32 Million USD	-3.8%
2005 Q2	262.93 Million USD	11.11%
2005 Q3	254.15 Million USD	-3.34%
2005 Q1	236.64 Million USD	-1.67%
2005 FY	275.41 Million USD	14.44%
2005 Q4	275.41 Million USD	8.36%
2004 Q4	240.66 Million USD	28.56%
2004 Q1	187.01 Million USD	-4.74%
2004 Q2	180.07 Million USD	-3.71%
2004 Q3	187.2 Million USD	3.96%
2004 FY	240.66 Million USD	22.6%
2003 Q3	153.37 Million USD	-3.4%
2003 Q2	158.76 Million USD	-3.95%
2003 Q1	165.29 Million USD	1.29%
2003 Q4	196.31 Million USD	28.0%
2003 FY	196.31 Million USD	20.29%
2002 Q4	163.19 Million USD	79.03%
2002 Q1	91.51 Million USD	-16.35%
2002 FY	163.19 Million USD	49.18%
2002 Q2	89.44 Million USD	-2.26%
2002 Q3	91.15 Million USD	1.92%
2001 Q3	97.3 Million USD	14.49%
2001 Q2	84.99 Million USD	94.15%
2001 FY	109.39 Million USD	165.93%
2001 Q4	109.39 Million USD	12.42%
2001 Q1	43.77 Million USD	6.42%
2000 FY	41.13 Million USD	89.57%
2000 Q2	33.75 Million USD	-5.5%
2000 Q3	29.14 Million USD	-13.67%
2000 Q1	35.72 Million USD	0.0%
2000 Q4	41.13 Million USD	41.17%
1999 FY	21.7 Million USD	-50.73%
1998 FY	44.04 Million USD	0.0%

Peer Total Liabilities Comparison of Exelixis, Inc.

Name	Total Liabilities	Total Liabilities Difference
BioNTech SE	2.76 Billion EUR	75.422%
CureVac N.V.	271.53 Million EUR	-149.859%
Biotest Aktiengesellschaft	945.4 Million EUR	28.237%
Biotest Aktiengesellschaft	945.4 Million EUR	28.237%
BRAIN Biotech AG	47.92 Million EUR	-1315.698%
Formycon AG	387.61 Million EUR	-75.032%
Heidelberg Pharma AG	21.01 Million EUR	-3128.656%
Medigene AG	10.65 Million EUR	-6270.376%

Global Stocks Search

Exelixis, Inc. (EX9.DE)

Total Liabilities Summary of Exelixis, Inc.

Annual Total Liabilities Chart of Exelixis, Inc. (2023 - 1998)

Historical Annual Total Liabilities of Exelixis, Inc. (2023 - 1998)

Peer Total Liabilities Comparison of Exelixis, Inc.